Immunovant (IMVT)
(Delayed Data from NSDQ)
$30.92 USD
+0.41 (1.34%)
Updated Jul 16, 2024 04:00 PM ET
After-Market: $30.92 0.00 (0.00%) 7:18 PM ET
4-Sell of 5 4
D Value D Growth C Momentum F VGM
Brokerage Reports
0 items in cart
Immunovant, Inc. [IMVT]
Reports for Purchase
Showing records 21 - 40 ( 105 total )
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
''1402 Confirms Profile and Ready to Move into the Clinic; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Optimized Entry and Exit Levels for IMVT 112123
Provider: Stock Traders Daily
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
With SAD and Early MAD Data in the Bank, Eyes Turn to Final Phase 1 MAD Readout; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
1402 Data Warrants a Reconsideration of the FcRn Space; PT Up to $47
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Near-Term Future of Immunovant Looks Catalyst-Rich; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
There?s Now Validation of the anti-FcRn Mechanism of Action in CIDP; Raise PT to $29; Reit. Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Takeaways From KOL Dinner Event on Navigating the anti-FcRn Competitive LandscapeThis report contains brief updates on the following: ARGX, IMVT. These companies are covered in more detail in separate Daily Notes and/or Company Reports.
Provider: H.C. Wainwright & Co., Inc.
Analyst: TSAO D
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Company: Immunovant, Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department